ClinMet recently announced that researchers from The University of California, San Diego School of Medicine and colleagues have published new findings that could fundamentally change understanding of how diabetes-related diseases develop – and how they might be better treated.
Research by ClinMet Scientific Founder and Colleagues Point to Enzyme that Restores Function in Diabetic Kidney Disease
Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, recently announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte’s oncology drug programs, beginning with the Incyte IDO1 inhibitor program. As part of the agreement, Ventana will support Incyte’s personalized medicine healthcare strategies for cancer drug development using its vast expertise in companion diagnostics, immunohistochemistry technology platforms, and worldwide customer support network.
WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic’s Center for Individualized Medicine
WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, recently announced a licensing agreement with Mayo Clinic’s Center for Individualized Medicine to expand WuXi’s collection of patient-derived xenograft (PDX) mouse models. These models will support the cancer drug discovery and personalized medicine efforts of WuXi’s global customers.
Landmark Study of More than 27,000 Women Shows Favorable Results of Roche’s CINtec PLUS Cytology Test
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.
Researchers Able to Identify that Benign Tumors from Use of Oral Contraceptive Have a Greater Chance of Becoming Malignant
Although very rare, the use of oral contraceptive can lead to benign tumors in the liver. The tumors, known as hepatocellular adenomas, can become malignant. It is, however, difficult for physicians to assess the risk of these tumors becoming malignant.
Surveyed EU5 Medical Oncologists Prescribe Iressa or Tarceva as a First-Line Treatment to an Average of 70 Percent of Their Confirmed EGFR-Mutation Positive NSCLC Patients
Interviewed payers say biomarker-driven prescribing is a non-small-cell lung cancer (NSCLC) market access lever, but optimal pivotal trial design is also key, according to a new report from Decision Resources.
Extensive Scientific Data Supports the Clinical Validity of Pharmacogenomic Testing for Predicting Patient Response to Psychiatric Medications
AssureRx Health, a leading personalized medicine company, recently announced that the International Review of Psychiatry published an extensive review that validates the clinical use of pharmacogenomic testing to help predict patient response to psychiatric medications and improve treatment outcomes.
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, recently announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.
Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
Researchers from GeneAssess, Inc., a Foundation Venture Capital Group portfolio company, recently announced the publication of the genetic studies that led to the identification of the FRY gene as a breast cancer susceptibility suppressor gene.